Alogliptin

Generic Name
Alogliptin
Brand Names
Incresync, Kazano, Nesina, Oseni, Vipidia
Drug Type
Small Molecule
Chemical Formula
C18H21N5O2
CAS Number
850649-61-5
Unique Ingredient Identifier
JHC049LO86
Background

Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

Indication

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Associated Conditions
Type 2 Diabetes Mellitus
Associated Therapies
-
Clinical Trials
Related News

The Practical Evidence of Antidiabetic Combination Therapy in Korea

First Posted Date
2014-09-03
Last Posted Date
2019-02-08
Lead Sponsor
Kun-Ho Yoon
Target Recruit Count
216
Registration Number
NCT02231021
Locations
🇰🇷

Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of

Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"

Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin
First Posted Date
2014-08-20
Last Posted Date
2019-11-06
Lead Sponsor
Takeda
Target Recruit Count
964
Registration Number
NCT02221284

Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy

First Posted Date
2014-02-21
Last Posted Date
2023-09-28
Lead Sponsor
Takeda
Target Recruit Count
374
Registration Number
NCT02068443

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: Alogliptin
First Posted Date
2013-10-17
Last Posted Date
2019-11-21
Lead Sponsor
Takeda
Target Recruit Count
19192
Registration Number
NCT01964963

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"

Completed
Conditions
Type 2 Diabetes Melitus
Interventions
Drug: Alogliptin
First Posted Date
2013-09-18
Last Posted Date
2016-09-27
Lead Sponsor
Takeda
Target Recruit Count
1374
Registration Number
NCT01945242

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

First Posted Date
2013-09-18
Last Posted Date
2019-11-19
Lead Sponsor
Takeda
Target Recruit Count
3317
Registration Number
NCT01945216

Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes

First Posted Date
2013-07-01
Last Posted Date
2016-11-28
Lead Sponsor
Takeda
Target Recruit Count
647
Registration Number
NCT01890122

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

First Posted Date
2012-08-14
Last Posted Date
2017-02-01
Lead Sponsor
AstraZeneca
Target Recruit Count
40
Registration Number
NCT01664624

DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

First Posted Date
2012-05-01
Last Posted Date
2012-10-19
Lead Sponsor
Nagaoka Red Cross Hospital
Target Recruit Count
500
Registration Number
NCT01588587
Locations
🇯🇵

Kurume University, Kurume, Fukuoka, Japan

🇯🇵

Nagaoka Red Cross Hospital, Nagaoka, Niigata, Japan

Study of Combination Therapy With SYR-322

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Alogliptin
Drug: Insulin
First Posted Date
2012-01-31
Last Posted Date
2013-11-13
Lead Sponsor
Takeda
Target Recruit Count
67
Registration Number
NCT01521962
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy